TABLE 1.
An overview of selected trials investigating sequential or concurrent radio-chemotherapy
| First author [ref.] | Year | Trial details | Chemotherapy regimen | Radiotherapy total dose | Radiotherapy single dose | 5-year OS |
| Bradley [1] | 2015 | Phase III | Carboplatin/paclitaxel (con) +/- cetuximab (cons) | 60 Gy | 2 Gy | 57.6% (2-year OS) |
| Carboplatin/paclitaxel (con) +/- cetuximab (cons) | 74 Gy | 2 Gy | 44.6% (2-year OS) | |||
| Oh [31] | 2013 | Phase III | Cisplatin/paclitaxel (con/cons) | 60–66 Gy | 2–2.4 Gy | Median OS 27.3 months |
| Cisplatin/docetaxel (con/cons) | 60–66 Gy | 2–2.4 Gy | Median OS 27.6 months | |||
| Cisplatin/gemzitabine (con/cons) | 60–66 Gy | 2–2.4 Gy | Median OS 16.5 months | |||
| Curran [30] | 2011 | Phase III | Cisplatin/vinblastin (con) | 60 Gy | 2 Gy | 16.0% |
| Cisplatin/vinblastin (seq) | 60 Gy | 2 Gy | 10.0% | |||
| Cisplatin/etoposide (con) | 69.6 Gy | 1,2 Gy twice a day | 13.0% | |||
| Segawa [32] | 2010 | Phase III | MVP (con) | 60 Gy | 2 Gy | 16.6% |
| Docetaxel/cisplatin (con) | 60 Gy | 2 Gy | 17.5% | |||
| Yamamoto [33] | 2010 | Phase III | MVP (con) | 60 Gy | 2 Gy | 17.5% |
| Carboplatin/irinotecan (con) | 60 Gy | 2 Gy | 17.5% | |||
| Carboplatin/paclitaxel (con) | 60 Gy | 2 Gy | 19.5% | |||
| Hanna [29] | 2008 | Phase III | Cisplatin/etoposide (con) | 59.4 Gy | 1.8 Gy | 26.1% (3-year OS) |
| Cisplatin/etoposide (con) + docetaxel (cons) | 59.4 Gy | 1.8 Gy | 27.1% (3-year OS) | |||
| Gouda [28] | 2006 | Randomised | Paclitaxel/carboplatin (con) | 60 Gy | 2 Gy | 45% (2-year OS) |
| Paclitaxel/carboplatin (ind/con) | 60 Gy | 2 Gy | 40% (2-year OS) | |||
| No chemotherapy | 60 Gy | 2 Gy | 10% (2-year OS) | |||
| Fournel [34] | 2005 | Phase III | Cisplatin/etoposide (con) | 66 Gy | 2 Gy | 21% (4-year OS) |
| Cisplatin/vinorelbine (seq) | 66 Gy | 2 Gy | 14% (4-year OS) | |||
| Zatloukal [35] | 2004 | Randomised | Cisplatin/vinorelbine (con) | 60 Gy | 2 Gy | 18.6% (3-year OS) |
| Cisplatin/vinorelbine (seq) | 60 Gy | 2 Gy | 9.5% (3-year OS) | |||
| Albain [36] | 2002 | Phase II | Cisplatin/etoposide (con) | 60 Gy | 2 Gy | 15.0% |
| Furuse [37] | 1999 | Phase III | MVP (con) | 56 Gy | 2 Gy | 15.8% |
| MVP (seq) | 56 Gy | 2 Gy | 9.0% | |||
| Lee [38] | 1996 | Phase II | Cisplatin/etoposide (con) | 69.6 Gy | 1,2 Gy twice a day | 35% (2-year OS) |
| Jeremic [39] | 1996 | Randomised | Carboplatin/etoposide (con) | 69.6 Gy | 1,2 Gy twice a day | 23% (4-year OS) |
| No chemotherapy | 69.6 Gy | 1,2 Gy twice a day | 9% (4-year OS) | |||
| Dillman [40] | 1996 | Phase III | Cisplatine/vinblastine (con) | 60 Gy | 2 Gy | 17% |
| No chemotherapy | 60 Gy | 2 Gy | 7% |
OS: overall survival; Con: concurrent; cons: consolidation; seq: sequential; MVP: mitomycin, vindesine, and cisplatin; ind: induction.